KR100245938B1 - 트리아졸릴티오메틸티오 세팔로스포린 염산염, 그의 결정성 수화물 및 이들의 제조방법 - Google Patents

트리아졸릴티오메틸티오 세팔로스포린 염산염, 그의 결정성 수화물 및 이들의 제조방법 Download PDF

Info

Publication number
KR100245938B1
KR100245938B1 KR1019930014742A KR930014742A KR100245938B1 KR 100245938 B1 KR100245938 B1 KR 100245938B1 KR 1019930014742 A KR1019930014742 A KR 1019930014742A KR 930014742 A KR930014742 A KR 930014742A KR 100245938 B1 KR100245938 B1 KR 100245938B1
Authority
KR
South Korea
Prior art keywords
hydrochloride
crystalline hydrate
crystalline
water
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1019930014742A
Other languages
English (en)
Korean (ko)
Other versions
KR940005636A (ko
Inventor
히사노리 다까하시
이데유따까
Original Assignee
시오노 요시히코
시오노기 세이야꾸 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 시오노 요시히코, 시오노기 세이야꾸 가부시키가이샤 filed Critical 시오노 요시히코
Publication of KR940005636A publication Critical patent/KR940005636A/ko
Application granted granted Critical
Publication of KR100245938B1 publication Critical patent/KR100245938B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D501/00Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cephalosporin Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1019930014742A 1992-07-31 1993-07-30 트리아졸릴티오메틸티오 세팔로스포린 염산염, 그의 결정성 수화물 및 이들의 제조방법 Expired - Fee Related KR100245938B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP92-204965 1992-07-31
JP20496592 1992-07-31

Publications (2)

Publication Number Publication Date
KR940005636A KR940005636A (ko) 1994-03-22
KR100245938B1 true KR100245938B1 (ko) 2000-04-01

Family

ID=16499234

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019930014742A Expired - Fee Related KR100245938B1 (ko) 1992-07-31 1993-07-30 트리아졸릴티오메틸티오 세팔로스포린 염산염, 그의 결정성 수화물 및 이들의 제조방법

Country Status (23)

Country Link
US (1) US5407929A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP0581552B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR100245938B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN1037683C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE165360T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU657866B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR9303235A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2101502A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE69318077T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2115725T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FI (1) FI933391L (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GR (1) GR3026699T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HU219637B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL106516A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX9304611A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO303734B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ248285A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PH (1) PH30109A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (2) PL172835B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (1) RU2118959C1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TW307769B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
UA (1) UA37181C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA935529B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS55023B1 (sr) * 2001-02-24 2016-11-30 Boehringer Ingelheim Pharma Derivati ksantina, njihovo dobijanje i njihova primena kao lekova
AT413282B (de) * 2002-02-01 2006-01-15 Sandoz Ag Kristalline salze der 7-(((5-amino-1,2,4-thiadiazol-3-yl) (fluoromethoxy-imino)acetyl)amino)-3- ((imino-1-piperazinylmethyl)
KR20030076759A (ko) * 2002-03-21 2003-09-29 주식회사 엘지생명과학 신규 세팔로스포린 화합물 및 그의 제조 방법
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US6727277B1 (en) 2002-11-12 2004-04-27 Kansas State University Research Foundation Compounds affecting cholesterol absorption
CA2513837A1 (en) 2003-02-12 2004-08-26 Paul Adriaan Van Der Schaaf Crystalline forms of pitavastatin calcium
PT1606293E (pt) 2003-03-27 2009-10-14 Basilea Pharmaceutica Ag Cefalosporina sob forma cristalina
US7501426B2 (en) * 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) * 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
BRPI0711558A2 (pt) 2006-05-04 2011-11-08 Boeringer Ingelheim Internat Gmbh polimorfos
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
KR101610005B1 (ko) * 2007-08-17 2016-04-08 베링거 인겔하임 인터내셔날 게엠베하 Fab 관련 질환의 치료에 사용하기 위한 푸린 유도체
PE20140960A1 (es) * 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR20190016601A (ko) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
AU2009281122C1 (en) * 2008-08-15 2016-04-21 Boehringer Ingelheim International Gmbh Purin derivatives for use in the treatment of fab-related diseases
EP2344195A2 (en) 2008-09-10 2011-07-20 Boehringer Ingelheim International GmbH Combination therapy for the treatment of diabetes and related conditions
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
NZ592924A (en) 2008-12-23 2014-05-30 Boehringer Ingelheim Int Salt forms of a xanthine derivative
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
KR20240090632A (ko) 2009-11-27 2024-06-21 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 dpp-iv 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
US9186392B2 (en) 2010-05-05 2015-11-17 Boehringer Ingelheim International Gmbh Combination therapy
EP3725325B1 (en) 2010-06-24 2023-05-31 Boehringer Ingelheim International GmbH Diabetes therapy
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
CN103781788B (zh) 2011-07-15 2016-08-17 勃林格殷格翰国际有限公司 经取代的喹唑啉、其制备及其在药物组合物中的用途
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
ES2929025T3 (es) 2012-05-14 2022-11-24 Boehringer Ingelheim Int Linagliptina, un derivado de xantina como inhibidor de dpp-4, para su uso en el tratamiento del SRIS y/o de la septicemia
EP2849755A1 (en) 2012-05-14 2015-03-25 Boehringer Ingelheim International GmbH A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
JP6615109B2 (ja) 2014-02-28 2019-12-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Dpp−4阻害薬の医学的使用
KR102391564B1 (ko) 2016-06-10 2022-04-29 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴 및 메트포르민의 병용물

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES475573A1 (es) * 1977-07-12 1980-01-16 Fujisawa Pharmaceutical Co Un procedimiento para preparar nuevos compuestos de cefem
IE65926B1 (en) * 1990-07-19 1995-11-29 Shionogi & Co Thioalkylthio cephalosporin derivatives

Also Published As

Publication number Publication date
IL106516A0 (en) 1993-11-15
RU2118959C1 (ru) 1998-09-20
NO303734B1 (no) 1998-08-24
TW307769B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1997-06-11
CN1037683C (zh) 1998-03-11
NO932745L (no) 1994-02-01
FI933391A7 (fi) 1994-02-01
EP0581552A2 (en) 1994-02-02
DE69318077D1 (de) 1998-05-28
EP0581552A3 (en) 1994-06-01
CA2101502A1 (en) 1994-02-01
NZ248285A (en) 1994-07-26
MX9304611A (es) 1994-02-28
DE69318077T2 (de) 1998-10-29
BR9303235A (pt) 1994-03-01
ZA935529B (en) 1994-02-24
FI933391L (fi) 1994-02-01
KR940005636A (ko) 1994-03-22
PL172830B1 (pl) 1997-12-31
GR3026699T3 (en) 1998-07-31
FI933391A0 (fi) 1993-07-29
UA37181C2 (uk) 2001-05-15
NO932745D0 (no) 1993-07-30
HUT68602A (en) 1995-06-28
PL299870A1 (en) 1994-02-07
AU657866B2 (en) 1995-03-23
PH30109A (en) 1996-12-27
AU4422793A (en) 1994-02-03
HU219637B (hu) 2001-06-28
PL172835B1 (pl) 1997-12-31
CN1089948A (zh) 1994-07-27
IL106516A (en) 1998-06-15
ES2115725T3 (es) 1998-07-01
HU9302194D0 (en) 1993-10-28
ATE165360T1 (de) 1998-05-15
US5407929A (en) 1995-04-18
EP0581552B1 (en) 1998-04-22

Similar Documents

Publication Publication Date Title
KR100245938B1 (ko) 트리아졸릴티오메틸티오 세팔로스포린 염산염, 그의 결정성 수화물 및 이들의 제조방법
RU1787158C (ru) Способ получени цефемовых соединений или их аддитивных солей с кислотами
RU2125571C1 (ru) СОЛЬ 7-([1α,5α,6α]-6-АМИНО-3-АЗАБИЦИКЛО [3.1.0] ГЕКС-3-ИЛ)-6-ФТОР-1-(2,4-ДИФТОРФЕНИЛ)-1,4- ДИГИДРО-4-ОКСО-1,8-НАФТИРИДИН-3-КАРБОНОВОЙ И МЕТАНСУЛЬФОНОВОЙ КИСЛОТ И СПОСОБ ЕЕ ПОЛУЧЕНИЯ
US20050245738A1 (en) Stable bioavailable crystalline form or cefdinir and a process for the preparation thereof
DK155943B (da) Analogifremgangsmaade til fremstilling af 7-d-(-)-alfa-amino-alfa-(p-acetoxyphenyl)acetamidocephalosporansyrer
CS207646B2 (en) Method of making the crystallic hydrated form of the sodium salt of the oximine derivative of the 7-aminothiazolylacetamidocephalosporan acid
US4263302A (en) Quinolinecarboxylic acid substituted penicillins and pharmaceutical compositions containing the same
EP0143658B1 (en) Improvements in or relating to cephalosporin derivatives
US5534508A (en) Cephem compounds and antimicrobial agents
AU2006300882A1 (en) Crystalline sodium salt of cephalosporin antibiotic
JPS6232194B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP2575590B2 (ja) トリアゾリルチオメチルチオセファロスポリン塩酸塩およびその水和物結晶ならびにそれらの製法
KR100195882B1 (ko) 신규한 세팔로스포린 결정
CZ284738B6 (cs) Způsob přípravy izolované krystalické formy 3/2 hydrátu 7-[(7-(S)-amino-5-azaspirol[2,4]heptal-5-yl]-8-chlor-6-fluor-1-[(1R,2S)-2-fluorcyklopropyl]-4-oxo-1,4-dihydrochinolin-3-karboxylové kyseliny
US6063778A (en) Cephalosporin derivatives and processes for the preparation thereof
KR100696422B1 (ko) 항생물질로서 사이클릭 아미노구아니딘 치환체를 가진세팔로스포린
EP0068403B1 (en) Cephalosporin compound
JP2000514832A (ja) 抗菌性の置換7−アシルアミノ−3−(メチルヒドラゾノ)メチルセファロスポリンおよび中間体
DE69312322T2 (de) Cephem verbindungen mit antimicrobizide eigenschaften
GB2091263A (en) 7-((carboxy-methoximino)-lh-pyrazol-3-yl-acetyl))-amino-3-desacetoxy-3-(l-methyl-lh-tetrazol-5-yl-thio)cepha 10-sporanic acid
IE49703B1 (en) Oxa-beta-lactam derivative
US5492903A (en) Crystalline esters of (+)-(5R, 6S)-6-[(R)-1-hydroxyethyl]-3-(3-pyridyl)-7-oxo-4-thia-1-azabicyclo[3.2.0]he
GB2100734A (en) New organic compounds processes for their production and their use
NO884417L (no) Monohydrat og solvater av et nytt beta-laktam-antibiotikumog fremgangsmaate for fremstilling derav.
GB2086375A (en) Thiazolidine derivatives with antibiotic activity

Legal Events

Date Code Title Description
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

G170 Re-publication after modification of scope of protection [patent]
PG1701 Publication of correction

St.27 status event code: A-5-5-P10-P19-oth-PG1701

Patent document republication publication date: 20000901

Republication note text: Request for Correction Notice

Gazette number: 1002459380000

Gazette reference publication date: 20000401

FPAY Annual fee payment

Payment date: 20021101

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20031203

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20031203